<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40934498</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1929-0748</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>JMIR research protocols</Title><ISOAbbreviation>JMIR Res Protoc</ISOAbbreviation></Journal><ArticleTitle>Assessing a Person-Centered and Culturally Sensitive Intervention for Arabic-, Turkish, or Urdu-Speaking Individuals With Type 2 Diabetes: Protocol for a Mixed Methods Realist Evaluation Study.</ArticleTitle><Pagination><StartPage>e69852</StartPage><MedlinePgn>e69852</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2196/69852</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Individuals from ethnic minority backgrounds have a 2.5 times higher incidence of type 2 diabetes (T2D) than ethnic Danes. They often face negative experiences with health care professionals, leading to unequal treatment. A person-centered and culturally adapted treatment approach can improve self-care, diabetes management, and treatment adherence.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This mixed methods realist evaluation (RE) protocol aims to understand how a person-centered and culturally sensitive course of treatment for T2D works, for whom it is most effective, and under what circumstances it is likely to be effective.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This RE is embedded within a 1-year randomized controlled trial, the Culturally Sensitive Course of Treatment for Individuals With T2D (ACCT2) study, for Arabic-, Turkish-, or Urdu-speaking individuals with suboptimal glycated hemoglobin (HbA<sub>1c</sub> ; &#x2265;53 mmol/mol) or unmet individual targets at 2 consecutive visits. The RE follows three phases: (1) developing, (2) testing, and (3) refining initial program theories. Data are collected through semistructured interviews at 4 months (visit 4) and at the end of the intervention (visit 6). Survey data are collected at baseline and at the end of the intervention. We aim to recruit 16 to 20 intervention participants, including at least 2 men and 2 women from each language group. Qualitative data will be analyzed thematically using a predefined codebook, and survey data will be analyzed descriptively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As of December 2024, a total of 13 visits and 4 interviews had been completed. All baseline survey responses have been collected, along with 2 survey responses at the end of the intervention. Data analysis is pending. The results will inform revisions to the initial program theories, refining a comprehensive model that captures interactions between context, mechanisms, and outcomes. We anticipate disseminating the findings in the first half of 2026.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This RE will support the randomized controlled trial by providing insights applicable to real-life clinical settings. The anticipated impact includes aiding the future development and implementation of interventions for the target groups.</AbstractText><AbstractText Label="INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)" NlmCategory="UNASSIGNED">DERR1-10.2196/69852.</AbstractText><CopyrightInformation>&#xa9;Mie Klarskov Jensen, Natasja Bjerre. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 11.09.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Mie Klarskov</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0009-0003-6182-7079</Identifier><AffiliationInfo><Affiliation>Steno Diabetes Center Copenhagen, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjerre</LastName><ForeName>Natasja</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8875-7240</Identifier><AffiliationInfo><Affiliation>Steno Diabetes Center Copenhagen, Herlev, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Res Protoc</MedlineTA><NlmUniqueID>101599504</NlmUniqueID><ISSNLinking>1929-0748</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724797">Turkish people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018912" MajorTopicYN="N">Arabs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054521" MajorTopicYN="Y">Cultural Competency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065246" MajorTopicYN="Y">Culturally Competent Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="N">Self Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094864" MajorTopicYN="Y">Middle Eastern People</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AI</Keyword><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">clinical protocols</Keyword><Keyword MajorTopicYN="N">health personnel</Keyword><Keyword MajorTopicYN="N">immigrants</Keyword><Keyword MajorTopicYN="N">minority groups</Keyword><Keyword MajorTopicYN="N">program evaluation</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">theoretical models</Keyword><Keyword MajorTopicYN="N">transients and migrants</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>16</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40934498</ArticleId><ArticleId IdType="doi">10.2196/69852</ArticleId><ArticleId IdType="pii">v14i1e69852</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>